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Figure 1. The compound 3360 inhibits the electron transport chain through
binding at the menaquinone site of Complex I.
An infection with H. pylori not only causes peptic ulcers but is 
also the leading cause of gastric cancer around the world. Over 
the last three decades there has been an increase in rate of 
infection due to ineffective H. pylori treatments. Currently, the 
patient is prescribed multiple broad-spectrum antibiotics and 
proton-pump inhibitor. However, this treatment is undesirable as 
it leads  to perturbation of the endogenous gut microbes.
Previously, our lab did a high-throughput screen in effort to 
combat H. pylori, yielding the compound 3169. 3360 (Fig.1) is 
the R-isomer of 3169 and is extremely potent towards H. pylori. 
We then further discovered that the site of action is Complex I of 
the Electron Transport Chain(ETC). The ETC is responsible for 
ATP production, but it is uniquely important in H. pylori as it is the 
only mechanism for energy production. 
ACKNOWLEDMENTS
RESULTS
Finding Cures. Saving Children
Figure 4. Molecular dynamic studies of compound 1 in complex with respiratory complex I. A. Average conformation over a 250ns molecular dynamic
simulation, showing key interactions to both the backbone and sidechains. B. The energy profile of 3360 in complex. C. Number of frames show




S. aureus E. coli Cytotoxicity
Compound ATCC 43504 SS1 ATCC 33591 MG1655 FaDu Glucose Galactose Glu/Gal Ratio
468883 <1.25 <0.039 >20 >20 >100 >100 8.47 11.80
470043 <1.25 0.323 >20 >20 >100 >100 57.1 1.75
219678 4.88 14.1 >20 >20 >100 >100 >100 1.00
135299 5.73 16.0 >20 >20 >100 >100 >100 1.00
468665 7.81 5.38 >20 >20 >100 >100 58.1 1.72
848619 9.58 8.20 >20 >20 >100 >100 27.3 3.66
084593 12.26 >40 >20 >20 >100 >100 <3.13 32.0
139937 15.81 5.30 >20 >20 >100 >100 80.6 1.24
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Figure 5. Selected compounds with H. pylori activity after a docking screen of ~10,000 compounds from the St. Jude Drug-Like library. A few ligands
show mitotoxicity (red highlighted) using a glucose-galactose assaysuggesting these ligands are acting on the electron transport chain.
Figure 3. Preliminary docking and validation studies. B.
Residues of the menaquinone binding pocket used to build the
docking grid in Glide. Known quinone binding (purple),
thienopyrimidine mutations (blue), and AstraZeneca
benzimidazole mutations (green). C. Compound 1 docked using
the docking grid, showing key interactions to C-terminal oxygen
of Thr400. D. The ROC curve from validation using 1% known
active compounds.




















3360 Hydrogen Bonds over 250ns
Hydrogen bond interactions over 
250ns


















Figure 2. Preliminary results of the thienopyrimidine series of ligands. A.
Selected compounds from the thienopyrmidine series for WT SS1 H. pylori
potency (blue) and SS1 NuoD A402P H. pylori mutant (purple).  B. Cytotoxicity 
of selected thienopyrmidine compounds in FaDu cells. C. Potency and toxicity 
of top ligand (3360), its enenantiomer (3361), and the racemate (3169). D. A 
map of possible reasons that 3360 has poor drug-like properties (Solubility:  
1.4 𝝁𝑴, Metabolic stability: 0.18 h, and Plasma protein binding: 99.4%)







3169 0.006 ± 0.003 0.105 ± 0.096 > 200 
3360 0.004 ± 0.000 0.061 ± 0.054 6.40 ± 0.01
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Conclusions
➢ Identification of highly potent ligand 3360 
➢ Mechanism of action discovered to be 
respiratory complex I 
➢ 3360 has poor drug-like properties
➢ Developed a validated docking protocol
➢ Virtual screen of the St. Jude Drug-like library, 
pre-filtered by Rule of 4
➢ 14 were active against H. pylori (14% of top 
compounds after VS)
➢ Active ligands are H. pylori specific
➢ Mitotoxicity studies suggest these compounds 
act on the electron transport chain.
Next Steps
➢ Test analogues of active ligands 
from virtual screen
➢ Confirm electron transport chain 
action using a SeaHorse assay
➢ Evaluate active ligands against 
mutant H. pylori strains for on 
target activity
➢ In vitro ADME on VS actives
➢ Virtual screen of the St. Jude 
libraries, filtered by Rule of 4
➢ Perform MD on most potent 
compounds
